IPR ruling supports strength of AbCellera IP, says Piper Sandler

After AbCellera announced that the USPTO’s Patent Trial and Appeal Board upheld the ‘408 patent on microfluidic cell culture technology and process in an Inter Partes Review filed by Berkeley Lights (BLI) that challenged AbCellera’s U.S. patent, Piper Sandler analyst Do Kim said he believes the IPR ruling supports the strength of AbCellera’s intellectual property, or IP, and the competitive advantage of its platform. The analyst, who noted that AbCellera intends to continue with the patent infringement case against Berkeley Lights, keeps an Overweight rating and $21 price target on AbCellera shares.